权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

FastHeal: A controlled-release dermal dressing for faster diabetes wound recovery

FastHeal：一种控释真皮敷料，可加快糖尿病伤口恢复

基本信息

批准号：
10045734
负责人：
金额：
$ 6.03万
依托单位：
MESOX LTD
依托单位国家：
英国
项目类别：
Grant for R&D
财政年份：
2022
资助国家：
英国
起止时间：
2022 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=10045734
关键词：
FastHeal controlled release dermal dressing

项目摘要

We propose to develop a novel medicated dressing containing a molecule that achieves faster diabetes wound healing. This is a problem affecting 450,000 individuals with diabetes in the UK alone. It costs the NHS £900M annually in care (healthcare visits) and treatment costs (antibiotics, bandages etc).We expect our dressing to be able to achieve twice as faster wound healing following diabetic pressure ulcers formation. This is because the molecule contained within is capable of encouraging faster growth of epithelial skin tissues at the affected wound site. This could lead to faster recovery from this debilitating complication and less risk for infection, sepsis and amputations. When pressure ulcers develop, patients could easily apply our dressing onto the affected area and recovery should be much quicker than traditional dressings.We expect to save the NHS £350M annually in costs related to out-patient and primary care costs using our innovation. The funding from IVUK will allow us to develop a product that is both affordable to the NHS and represents good value for money for UK taxpayers. The primary beneficiaries will be patients living with diabetes and suffering from its complications as well as NHS which is already under immense cost and capacity pressures.

我们建议开发一种新的含药敷料，其中含有一种分子，可以实现更快的糖尿病伤口愈合。这是一个问题，仅在英国就影响着45万糖尿病患者。它每年花费NHS 9亿英镑的护理（医疗保健访问）和治疗费用（抗生素，绷带等）。我们希望我们的敷料能够在糖尿病压疮形成后实现两倍的伤口愈合速度。这是因为其中所含的分子能够促进受影响伤口部位的上皮皮肤组织更快地生长。这可能导致更快地从这种使人衰弱的并发症中恢复，并降低感染，败血症和截肢的风险。当压力性溃疡发生时，患者可以很容易地将我们的敷料应用到受影响的区域，并且恢复应该比传统敷料快得多。我们预计使用我们的创新每年可以为NHS节省3.5亿英镑的门诊和初级护理费用。来自IVUK的资金将使我们能够开发一种产品，既能让NHS负担得起，又能为英国纳税人带来物有所值的回报。主要受益者将是患有糖尿病和并发症的患者以及已经面临巨大成本和容量压力的NHS。